How Much Does Cologuard Test Cost?

Published on February 18, 2026 | Prices Last Reviewed for Freshness: March 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Cologuard is an at-home stool DNA screening test prescribed by a clinician and processed by a lab to help screen for colorectal cancer in people at average risk. In real life, what you pay ranges from $0 to several hundred dollars because coverage rules, network status, and where you are in your plan year (deductible met or not) can matter as much as the test itself.

Your total cost typically comes from five components: the lab charge or allowed amount, how your plan treats preventive screening, whether the lab is considered in-network, any deductible or coinsurance that applies, and the downstream cost of follow-up testing if your result is positive.

TL;DR: Many people pay $0 for screening, but self-pay and deductible situations can push the out-of-pocket cost into the hundreds.

• Cologuard Plus lists a self-pay price of $790 (as of the current Cologuard Plus page).
• Medicare covers multi-target stool DNA screening every 3 years and says you pay $0 if eligibility conditions are met and the provider accepts assignment.
• A public fee-schedule benchmark shows $508.87 for CPT 81528 in a 2025 state clinical lab rate document (allowed amounts vary by payer and contract).
• National screening guidance commonly starts average-risk adults at age 45, which can influence preventive coverage language.

How Much Does Cologuard Test Cost?

If you are paying cash, the clearest published “self-pay” number is for Cologuard Plus. The company states that paying out of pocket costs $790 on the Cologuard Plus overview page.

That self-pay figure is not the same thing as what Medicare or an insurer may allow on a claim. A public benchmark for an allowed amount can show up in fee schedules. For example, Kentucky’s 2025 clinical lab rates document lists $508.87 for CPT 81528 under gene analysis for colorectal cancer, in the 2025 Clinical Lab Rates PDF. That does not mean every plan pays that amount, but it does illustrate how “allowed” can differ from self-pay pricing.

Comparing the two published reference points, $790 minus $508.87 equals $281.13 ($790 − $508.87 = $281.13). That gap is one reason two people can talk about “the price” and be describing different layers of pricing (cash pay versus payer-allowed).

What the Cologuard test is

Cologuard sits in the broader landscape of colorectal cancer screening options that includes stool-based tests (like FIT), imaging tests, and colonoscopy. The stool DNA approach is designed for average-risk screening, meaning it is generally intended for people without symptoms and without higher-risk conditions that often shift recommendations toward colonoscopy-based surveillance.

Cost discussions get complicated because “screening” and “diagnostic” can trigger different benefit rules. The stool DNA test is typically treated as a preventive screening tool. If the result is positive, follow-up evaluation is usually recommended. That next step is a major reason the “real cost” picture can be bigger than the kit that arrives at your door, even when the screening itself is covered as preventive.

Guidelines shape eligibility language. The U.S. Preventive Services Task Force recommends colorectal cancer screening for adults ages 45 to 75, with selective screening for ages 76 to 85 depending on individual factors, as laid out in the USPSTF colorectal screening recommendation.

How insurance coverage usually works

Many insured patients do pay $0 for screening, but the fine print is always about eligibility and how the claim is processed. UP-front, the practical questions are billing questions: whether the test is treated as preventive for your age and risk category, whether the lab pathway is considered in-network for your plan, and whether any prior authorization or ordering rules apply.

Coverage law provides a helpful backdrop, but it does not eliminate edge cases. The American Cancer Society summarizes how federal coverage rules apply to colorectal cancer screening and why cost-sharing can still show up depending on plan type and circumstances in its screening coverage and cost-sharing overview (last revised Oct 15, 2025). The takeaway for consumers is that “covered” can still turn into a bill when definitions, coding, or network status don’t line up the way you expected.

When you want a simple baseline before calling your insurer, it helps to know what the company says about coverage pathways and self-pay. The Cologuard insurance page frames the test around Medicare coverage and expanding commercial coverage, and it repeats the $790 self-pay price for Cologuard Plus as a cash-pay anchor.

Medicare rules

Medicare’s public coverage language for multi-target stool DNA screening is unusually direct. Medicare lists the service as a Part B preventive benefit covered every 3 years and says you pay $0 if your provider accepts assignment on the multi-target stool DNA coverage page.

Eligibility details still matter. Medicare’s preventive services handbook includes an eligibility band (including ages 45–85) and “average risk” conditions for coverage frequency, described in Your Guide to Medicare Preventive Services (PDF). In cost terms, this sets up the cleanest case: eligible screening on schedule, ordered appropriately, with assignment accepted, usually results in $0 out of pocket.

Medicaid and state program

Medicaid is not one uniform national policy. States and managed care organizations can publish specific criteria tied to billing codes and age bands, and those details can change. One example is a North Carolina Medicaid bulletin that updates age criteria for CPT 81528 (Cologuard) in the May 15, 2023 policy notice.

This variability is why Medicaid members should treat the state program or managed care plan guidance as the reference point, not anecdotal “what I paid” posts. If you want the most useful pre-test estimate, ask the plan (or the ordering clinic’s billing staff) to confirm: coverage for the code used, the frequency rule, and whether the ordering clinician and lab pathway match the plan’s network arrangement.

For plain-language context on who is generally targeted for screening, CDC’s public health overview frames screening for adults ages 45 to 75 on the CDC colorectal cancer screening page (updated Feb 26, 2025). Program rules still vary, but the age band helps explain why many coverage policies anchor around mid-40s eligibility for average-risk adults.

Hidden costs

A consumer-focused explanation of the “what happens next” reality for stool-based screening appears in Cancer Today’s discussion of at-home colorectal screening test costs, which notes that a positive stool test commonly leads to colonoscopy follow-up. That downstream pathway is often the largest financial swing factor in real-life screening costs.

For many households, the billing outcome turns less on the kit and more on preventive eligibility, network handling, and whether follow-up care is needed.

Cologuard vs colonoscopy

People often compare Cologuard to colonoscopy because both are used in colorectal cancer screening, but they do not behave the same way in insurance billing or in care pathways. Stool DNA screening is a lab-based screening method you do at home. Colonoscopy is an in-facility procedure that can include sedation and may include biopsy or polyp removal, which changes the billing footprint.

For readers who want a real-world look at how colonoscopy bills can be composed, the colonoscopy cost article is useful for understanding why facility-related components can dominate in some settings. This matters for Cologuard budgeting because follow-up colonoscopy is a common next step after a positive stool DNA result, so the “screening cost” story is incomplete if you ignore the potential downstream procedure.

Mini cases

Mini case 1 (Medicare-eligible screening): A beneficiary who meets eligibility requirements for multi-target stool DNA screening and uses a provider who accepts assignment can reasonably expect $0 out of pocket for screening on the covered schedule. This is the cleanest “patient price” scenario.

Mini case 2 (self-pay Cologuard Plus): A cash-pay patient using the Cologuard Plus self-pay pathway would plan around $790 as the test price, before any additional follow-up testing.

Mini case 3 (state fee-schedule benchmark context): A patient whose plan’s allowed amount resembles published fee schedule benchmarks might see claim pricing closer to figures like $508.87 for CPT 81528, while the patient share still depends on preventive processing and deductible status.

Worked example (itemized planning using cited numbers): Start with the Cologuard Plus self-pay price of $790. If you spread that across Medicare’s 3-year screening cadence as a planning exercise, the average “per-year equivalent” is about $263.33 ($790 ÷ 3 ≈ $263.33). That is not how you are billed, but it helps cash-pay households translate a one-time test into a longer-term screening budget frame.

If a household set aside $25 per month for 12 months, that savings equals $300 ($25 × 12 = $300). Compared with a $790 self-pay test, that leaves a shortfall of $490 ($790 − $300 = $490). This is why self-pay screening often feels like a single-event expense rather than a small monthly add-on.

How to reduce out-of-pocket costs

Cost control for Cologuard is mostly administrative. If you have commercial insurance, confirm the test is covered as preventive screening for your age and risk category, and confirm the lab pathway is considered in-network. If your plan has any ordering rules, confirm them before the order is placed. For Medicaid, rely on your state program or managed care plan guidance and confirm code and eligibility rules up front.

It also helps to keep your screening plan organized. A routine preventive care visit is often where screening gets ordered, so a basic sense of preventive visit and lab pricing can help you spot when something is being billed outside the “preventive” lane. For broader lab-cost context, the blood test cost overview shows how pricing can vary based on payer contracts and coding, which is the same core dynamic that shows up with stool DNA screening. For the appointment layer, the annual physical exam cost page is a reminder that preventive care can still generate costs when services get billed outside preventive rules.

Cost snapshot table

Article Highlights

• Cologuard Plus lists a self-pay price of $790, which is the clearest cash-pay anchor for the current product page.
• Medicare covers multi-target stool DNA screening every 3 years and says eligible patients pay $0 when assignment is accepted.
• A published 2025 lab fee schedule shows a benchmark of $508.87 for CPT 81528, illustrating how allowed amounts can differ from self-pay pricing.
• The biggest cost surprise is often follow-up evaluation after a positive result, not an extra fee on the kit itself.
• Most avoidable bills come from administrative issues (preventive vs diagnostic processing, network handling, and frequency rules), so a short pre-order billing check can save real money.

Answers to Common Questions

How much is Cologuard if you pay out of pocket?

Cologuard Plus lists $790 as the self-pay price on the company’s product page, and that amount is separate from any insurance-allowed pricing.

Does Medicare pay for Cologuard?

Medicare describes multi-target stool DNA tests as a Part B preventive service covered every 3 years for eligible people, and says you pay $0 if your provider accepts assignment.

Why do I see different prices like $790 and $508.87?

The $790 figure is a published self-pay price for Cologuard Plus, while $508.87 appears as a fee-schedule benchmark for CPT 81528 in a 2025 state lab rate document. Self-pay pricing and payer-allowed amounts can differ.

What costs should I plan for if the result is positive?

A positive stool-based screening result commonly leads to follow-up evaluation, which can include a colonoscopy and additional facility-related charges depending on setting and what is done.